Nintedanib, a therapy used to treat patients with idiopathic pulmonary fibrosis (IPF), may increase the risk of bleeding, potentially because of its mechanism of action.

Analysis from EMPIRE, a real-world database of patients with IPF, found that nintedanib, compared with pirfenidone, was received less frequently in patients being treated with anticoagulant medications.

Overall, the incidence of bleeding in patients with IPF was low (0.29%).